ESC Premium Access

Effects of the PAR-1 receptor antagonist vorapaxar on platelet activation and coagulation biomarkers in patients with stable coronary artery disease

Congress Presentation

About the speaker

Mrs Renske Olie

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))
0 follower

8 more presentations in this session

Six-month treatment with novel oral anticoagulants ameliorates cerebral blood flow, as evaluated with brain perfusion SPECT.

Speaker: Doctor H. Takeuchi (Ogachi, JP)

Thumbnail

TAFI level dynamics during long-term warfarin therapy as a predictor of recurrent bleedings in a target INR

Speaker: Professor N. Vorobyeva (Moscow, RU)

Thumbnail

Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

Speaker: Doctor M. Krempf (Nantes, FR)

Thumbnail

Evaluation of the pharmacokinetics and pharmacodynamics of subcutaneously administered dutogliptin for daily injection with granulocyte colony stimulating factor (G-CSF) for AMI

Speaker: Mr D. Nix (Lexington Township, US)

Thumbnail

Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results

Speaker: Doctor M. Bonaca (Aurora, US)

Thumbnail

Access the full session

Innovative drug therapies

Speakers: Mrs R. Olie, Doctor H. Takeuchi, Professor N. Vorobyeva, Doctor M. Krempf, Mr D. Nix...
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb